Valuation: Insulet Corporation

Market Cap 10.97B 9.64B 8.96B 8.22B 15.45B 1,056B 15.69B 106B 41.57B 519B 41.18B 40.29B 1,796B P/E 2026 *
25.6x
P/E 2027 * 19.9x
Enterprise Value 11.05B 9.7B 9.02B 8.28B 15.55B 1,064B 15.79B 107B 41.86B 523B 41.46B 40.57B 1,808B EV / Sales 2026 *
3.33x
EV / Sales 2027 * 2.72x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insulet Corporation

1 day+3.08%
1 week-0.49%
Current month+7.23%
1 month+9.66%
3 months-13.87%
6 months-39.83%
Current year-42.56%
1 week 157.44
Extreme 157.44
168.25
1 month 148.02
Extreme 148.02
169.85
Current year 138.79
Extreme 138.79
299.8
1 year 138.79
Extreme 138.79
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 30.69
Extreme 30.69
354.88
Manager TitleAgeSince
Chief Executive Officer 55 28/04/2025
Director of Finance/CFO 53 30/09/2025
Compliance Officer 50 01/12/2022
Director TitleAgeSince
Chairman 61 01/01/2019
Director/Board Member 61 27/07/2015
Director/Board Member 59 10/08/2017
Date Insider Type Main position Quantity % Market Cap.
7/1/26 A Free

Director

1,355 0.0019%
7/1/26 A Other

Director

0 0%
6/30/26 A Free

Director

144 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+3.08%-0.49%-43.03%-41.61% 10.97B
+2.29%+2.36%-17.97%-10.09% 175B
+1.46%+0.01%-9.87%-6.25% 105B
+1.58%+0.65%+6.69%+61.86% 59.35B
-1.13%-1.96%+32.11%+56.38% 50.71B
+2.22%-1.14%-14.85%-44.15% 42.15B
+2.98%-2.61% - - 31.82B
+1.50%-6.67%-17.52%-43.99% 27.2B
-7.67%-8.39%+17.59%-12.73% 25.11B
+1.63%-1.73%-5.80%-7.80% 20.53B
Average +0.70%-3.10%-5.85%-5.37% 54.83B
Weighted average by Cap. +1.22%-1.49%-6.61%+0.22%

Financials

2026 *2027 *
Net sales 3.32B 2.92B 2.71B 2.49B 4.68B 320B 4.75B 32.2B 12.58B 157B 12.46B 12.19B 543B 3.93B 3.45B 3.21B 2.94B 5.53B 378B 5.62B 38.09B 14.88B 186B 14.74B 14.42B 643B
Net income 432M 379M 353M 324M 608M 41.61B 618M 4.19B 1.64B 20.46B 1.62B 1.59B 70.73B 564M 496M 461M 423M 795M 54.33B 807M 5.47B 2.14B 26.71B 2.12B 2.07B 92.35B
Net Debt 75.17M 66.02M 61.4M 56.34M 106M 7.24B 107M 729M 285M 3.56B 282M 276M 12.3B -283M -248M -231M -212M -398M -27.25B -405M -2.74B -1.07B -13.39B -1.06B -1.04B -46.31B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
24/07/26 $163.26 +3.08% 1,147,579
23/07/26 $158.38 -0.35% 1,141,160
22/07/26 $158.93 -2.93% 1,376,513
21/07/26 $163.72 -2.18% 1,145,480
20/07/26 $167.37 +2.02% 1,652,989
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
158.38USD
Average target price
238.22USD
Spread / Average Target
+50.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock